Interleukin-12 gene therapy - Valentis

Drug Profile

Interleukin-12 gene therapy - Valentis

Latest Information Update: 19 Sep 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dana-Farber Cancer Institute; University of Pennsylvania; Valentis
  • Class Antineoplastics; Cytokine genes; Gene therapies; Interleukins
  • Mechanism of Action Interleukin 12 stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Head and neck cancer; Malignant melanoma

Most Recent Events

  • 19 Sep 2006 Discontinued - Phase-II for Head and neck cancer in USA (Intratumoural)
  • 19 Sep 2006 Discontinued - Phase-II for Malignant melanoma in USA (unspecified route)
  • 15 Jan 2002 Valentis reduces its preclinical product development efforts and suspends its programs in oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top